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Abstract The chronic nature of rheumatoid arthritis (RA)
suggests immune dysfunction, including persistent systemic
activation. Therefore, we evaluated the activatory and inhibi-
tory potential as well as proliferative activity of peripheral
blood (PB) CD4+ T cells from RA patients in different stages
of the disease and after different therapeutic interventions. We
found that CD4+ T cells from RA patients were activated
in vivo concerning decreased CD28 expression and increase
of CD40L, CD69, and CTLA-4 expression; however, the
extent of stimulation was suboptimal when compared to
healthy controls. Consequently, impaired proliferative activi-
ties of these cells were found in all patients irrespective of the
active disease duration. Treatment with methotrexate (MTX)
and/or inhibitors of TNF-alpha (iTNF) did not significantly
influence systemic activation in RA patients, which
corresponded with the maintenance of inflammation markers;
however, partial restoration of CD28 and CTLA-4 expression
as well as clinical improvement were observed. In patients
with early disease (the MTX group), we noted higher capacity
of CD4+ T cells for restoration of T cell function, whereas
cells from the iTNF group with progressive disease remained
with a proliferative defect after the treatment. In conclusion,
our study demonstrates that the dysregulated expression of
molecules interfering with CD4+ Tcell signalingmay result in
functional impairment of the effector T cells and correlates
with disease progression.
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Abbreviations
ACR American College of Rheumatology
CRP C-reactive protein
CTLA-4 Cytotoxic T-lymphocyte antigen-4
cCTLA-4 Cytoplasmic CTLA-4
DAS28 Disease activity score
ESR Erythrocyte sedimentation rate
EULAR European league against rheumatism





mRNA Messenger ribonucleic acid
MTT Methyl thiazol tetrazoliumbromide
OD Optical density
OKT3 Ortho kung t3
PB Peripheral blood
PBMC Peripheral blood mononuclear cells
RA Rheumatoid arthritis
Th Helper T cell
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease charac-
terized by swollen and tender joints, cartilage damage, the
production of autoantibodies, and systemic inflammation as a
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hallmark of disease progression. The pathogenesis of RA
includes T cells’ contribution to initiation and maintenance
of the disease. The persistent inflammatory process in RA is a
result of disturbed B or T cell stimulation including
autoreactive T cells, which initiate a stimulating cascade of
events [1].
Immune homeostasis requires optimal T cell activation. A
major role in the maintenance of balanced T cell responses is
played by CD28, CD40L, and CTLA-4 molecules. CD28 is
an antigen constitutively expressed on T cells transducing a
costimulatory signal after ligand B7 binding, thus promoting
full T cell activation [2], whereas both CD40L and CTLA-4
are inducible upon activation, thus being transiently expressed
on the cell surface of T lymphocytes [3, 4]. The cross-linking
of CTLA-4 during T cell activation results in suppression of
cytokine production and cell proliferation [4]; hence CTLA-4
is suggested to be an antagonist of CD28 [5]. They both
share common B7 ligands with obviously higher affinity
displayed by CTLA-4. Reciprocal regulation of CD28 and
CTLA-4 at the mRNA level has been previously demon-
strated; in particular, transient down-regulation of CD28
mRNA seen early after stimulation is a stronger inducer of
CTLA-4 gene transcription [6]. CD40L, one of the earliest
and the most specific marker of T cell activation, is
crucially involved in the positive cell signaling process
after binding to CD40 expressed on B cells [7]. Thus,
CD40-CD40L interactions are involved in both humoral
and cellular immune responses, including autoimmune ac-
tivity and inflammation [3].
Several studies showing genetic associations of CD28 and
CTLA-4, their increased soluble form as well as clinical
improvement of RA after CTLA-4Ig administration clearly
emphasize the importance of both signaling molecules in the
pathogenesis of RA [8–10]. Also, CD40L expression has been
found to be significantly higher in the circulation of RA
patients [11, 12]. Furthermore, a long-lasting remission of
experimental autoimmune diseases has been achieved by
blocking CD40L, suggesting its role in the pathological mech-
anisms of RA as well [13].
Previous studies, including observations from our labora-
tory, have shown that progression/severity of RA might be
accompanied by systemic CD4+ T cell subtypes imbalance
[14, 15, unpublished data]. The present study was undertaken
to assess whether disease evolution may affect the activatory
and inhibitory potential of CD4+ T cells. Therefore, we
evaluated the expression of CD28, CD40L, and CTLA-4
molecules in the population of peripheral blood (PB) helper
T cells from RA patients in the different stages of the
disease. Furthermore, we performed a proliferation assay
to find out if the state of activation of CD4+ T cells may
influence their function. We also examined the impact of




The study was approved by the Ethics Committee ofWroclaw
Medical University. Peripheral blood was taken from 36 pa-
tients (26 women and 10 men) diagnosed with RA based on
the 1987 revised classification criteria of the American Col-
lege of Rheumatology (ACR). Patients were divided into 2
groups depending on the severity and duration of the disease;
19 patients, including 12 women and 7 men (mean age: 54.7±
16.4 years), with a mean disease duration of 15.2 months were
assigned to methotrexate therapy (MTX group). Seventeen
patients, including 14 women and 3 men (mean age: 50.1±
6.9 years), with a mean RA duration of 123.7 months were
assigned to therapy with inhibitors of TNF-alpha (iTNF
group). Blood samples were collected just before and after
6 months of the therapy.
All the patients had active disease and were consistent with
the criteria of the activity: for methotrexate (MTX) treatment,
erythrocyte sedimentation rate (ESR) > 30 mm/h and/or
C-reactive protein (CRP) > 1.5 mg/dL, disease activity score
DAS28>3.2; for treatment with inhibitors of the human tumor
necrosis factor alpha (iTNF), ESR > 30 mm/h and/or CRP >
1.5 mg/dL, DAS28>5.1. Treatment failure with at least two
traditional disease-modifying antirheumatic drugs
(DMARDs), including MTX, was required for biologics to
be used. Therefore, based on the statistically significant dif-
ferences in the active disease duration (p =0.0000001) and a
mean DAS28 score either before (5.6±0.9 vs. 6.2±0.8,
p =0.02) or after the treatment (3.3±1.2 vs. 4.8±1.1,
p =0.0001) between the two groups, iTNF patients were
assigned to the progressive form of the disease.
All patients from the MTX group were receiving a stable
dose of MTX (10–15 mg once a week orally) alone; in the
biologic treatment group, patients received recommended
doses of the following inhibitors of TNF-alpha: infliximab,
etanercept, and adalimumab. Due to the persistently active
disease, iTNF patients were also treated with DMARDs,
including MTX (n =15), sulphasalazine (n =9), non-steroidal
anti-inflammatory drugs (n =17), and glucocorticoids at a
daily dose of less than 10 mg of prednisone (n =16), if the
treatment regimens were not modified 4 weeks before the
study; hence, 13 and 3 out of 17 patients were still receiving
MTX and sulphasalazine, respectively, when iTNF therapy
was started. With regard to the MTX group, patients were
treated with unmodified doses of steroids (n =13) and/or anti-
inflammatory drugs (n =16) for more than 4 weeks before
MTX administration.
Also the clinical and biochemical parameters allowed de-
termination of the improvement according to the criteria sug-
gested by the European League Against Rheumatism
(EULAR): no response if reduction of DAS28<0.6; moderate
236 A. Kosmaczewska et al.
efficacy of the therapy if reduction is 0.6<DAS28<1.2; and
good efficacy of the therapy if reduction of DAS28>1.2. Al-
though at least partial improvement was achieved in 14
(82.35 %) and 19 (100 %) patients administered with iTNF
andMTX, respectively, only 3 out of 19MTX patients and none
of 17 iTNF patients reached clinical remission (DAS28<2.6) at
6 month of the therapy. Eighteen age- and sex-matched healthy
controls, including 14 women and 4 men (mean age: 51.8±
8.4 years), free of inflammatory syndrome (CRP < 0.5 mg/dL),
infectious diseases, steroid or immunosuppressive therapy, and
cancers were also included in the study. Written informed con-
sent was obtained from each patient and healthy donor after a full
explanation of the procedure.
Cell Preparation, Culture Conditions, and Flow Cytometry
Peripheral blood mononuclear cells (PBMCs) were obtained
by buoyant density-gradient centrifugation on Lymphoflot
(Biotest, Germany). The expression of CD28, CD40L
(CD154), CD69, and CTLA-4 molecules was studied on the
freshly isolated and cultured for 48 h CD4+ T cells by a triple
immunostaining method. After isolation the cells were stained
with anti-CD3/FITC, anti-CD4/PerCP, and anti-CD28/RPE,
anti-CD40L(CD154)/RPE, anti-CD69/RPE or anti-CTLA-
4(CD152)/RPE monoclonal antibodies (MoAbs) (Becton
Dickinson). For intracellular detection of CTLA-4, the cells
were first incubated with pure anti-CTLA-4 MoAb to block
surface CTLA-4 molecules with subsequent fixation, perme-
abilization, and staining with anti-CTLA-4/RPE MoAb as
described above.
For estimation of the optimal range of CD4+ T cells acti-
vation, the PBMCs from healthy individuals were suspended
in 1×106 PBMCs/ml in RPMI-1640 medium (Gibco, Paisley,
UK) supplemented with 10 % fetal calf serum (Flow Labora-
tories, UK), 2 mmol/l L-glutamine and 50 μg/ml gentamycin
(Gibco), and cultured with 10 ng/ml of anti-CD3 monoclonal
antibody (MoAb) (clone OKT3) (eBioscience). The cultures
were incubated at 37 °C in a humidified atmosphere contain-
ing 5 % CO2 for 48 h. Then, immunostaining with markers of
activation and inhibition was performed as described above.
For each immunostaining procedure, negative controls were
always done by omitting the MoAb and by incubating the
cells with mouse Ig of the same isotype as the MoAbs conju-
gated with PerCP, FITC or RPE. The cells were analyzed by
flow cytometric analysis using a FACScan cytometer
equipped with Cell Quest software (BD Bioscience
Pharmingen). Of the acquired 10,000 events, at least 1,500–
2,000 were analyzed in the final histograms.
Proliferation Assays
Cell proliferation was analyzed using the colorimetric methyl
thiazol tetrazoliumbromide (MTT) method. After negative
separation by magnetic cell sorting (Miltenyi Biotec), CD4+
Tcells were cultured at 1×105 cells/200 μl in 96-well plates in
medium alone or with anti-CD3 monoclonal antibody (10 ng/
ml) for the induction of cell proliferation. The plates were
incubated at 37 °C in a humidified atmosphere containing 5 %
CO2 for 48 h. After 48 h, 25 μl of MTT (5 mg/ml stock
solution) was added to each well and incubated for 3 h. Next,
90 μl of the extraction buffer (20 % sodium dodecyl sulfate
with 50 % dimethylformamide, pH 4.7) was added. After 4 h
of incubation, the optical density (OD) was measured at
550 nm using the microplate reader (Dynatech 5000). The
experiments were repeated 3 times.
Statistical Analysis
One-way ANOVA test was used to determine significant
differences between groups. The Wilcoxon signed rank test
was used to compare paired patients before and after the
treatment. Results were considered statistically significant




Expression of Co-Stimulatory CD28 Molecule and Activation
Markers in PB CD4+ T Cells
The frequencies of CD4+ T cells co-expressing CD28,
CD40L, CD69, and both membrane/surface and cytoplasmic
CTLA-4 molecule (mCTLA-4 and cCTLA-4, respectively)
were estimated to define the activation status of the PB
CD4+ T cells. The mean frequencies of CD28+, CD40L+,
CD69+ Th cells in all groups examined are shown in Table 1
and Fig. 1.
Although the differences were of borderline significance
(p ≤0.06), the proportions of CD4+CD28+ T cells within
PBMCs were obviously lower in RA patients in comparison
with corresponding cells from controls. OKT3 stimulation
decreased the CD28+ population in all examined individuals,
but only in the iTNF patients was it compromised to signifi-
cantly lower values compared to controls (p =0.001).
The population of in vivo activated T cells with the respec-
tive phenotype CD4+CD40L+ and CD4+CD69+ was signif-
icantly increased in early (p ≤0.00001) as well as in progres-
sive disease (p <0.002) compared to controls; remarkably,
among the patients, the activated CD4+ T cell population
was higher in MTX patients (p ≤0.04). The expression of
antigen CD69 on PB cells did not reach the physiological
values observed in optimally ex vivo stimulated T cells from
controls, remaining at significantly lower levels in all patients
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(p <0.002). Stimulation with OKT3 revealed no impact on the
frequency of CD40L+ Tcells only in iTNF patients, whereas a
decrease in MTX patients (p =0.006) and an increase in con-
trols were found (p =0.001). OKT3-stimulated CD40L ex-
pression on Th cells was comparable between all individ-
uals studied. As for CD69 expression, we observed a
further significant increment after ex vivo stimulating cul-
ture in all studied groups (p <0.004), although its level in
iTNF patients did not reach values observed in controls
(p =0.02).
The expression of inhibitory CTLA-4 molecule in the CD4+
T cell population is shown in Table 1 and Fig. 2. Only in MTX
patientswas themCTLA-4molecule expressed on a significantly
higher proportion of CD4+ T cells compared to controls (p=
0.02). In contrast, the expression of the cCTLA-4 molecule was
diminished in the iTNF group as compared to either correspond-
ing cells from MTX patients (p =0.008) or to the optimally
ex vivo stimulated cells from healthy controls (p=0.04). OKT3
stimulation resulted in no changes in the mCTLA-4+ T cell
population in MTX patients, and its marked increase in others
(p≤0.04). Thus, there were no differences in ex vivo stimulated
mCTLA-4 expression between studied groups. As regards
cCTLA-4 expression, stimulating culture led to significant in-
crease in controls only (p=0.003), whereas it decreased, howev-
er non-significantly, in the MTX group. In iTNF patients, OKT3
stimulation did not significantly change the frequency of
cCTLA-4+ Th cells; thus its defective proportion in RA was
sustained in comparison with controls (p ≤0.02).
Proliferative Capacity of PB CD4+ T Cells
In order to verify whether the affected capacity of reaching the
optimal level of T cell activation in circulation of RA patients
may result in subsequent functional impairment of these cells,
we performed a proliferation assay. Compared to controls, we
found that both groups of patients exhibited defective prolif-
erative activity of CD4+ T cells under either unstimulated or
OKT3-stimulated conditions (p ≤0.01 and p ≤0.006, respec-
tively). Although the differences between patients were non-
significant, the functional impairment of Tcells was evident in
the iTNF group. The results are provided in Table 2.
After 6 Months of Therapy
Expression of Co-Stimulating CD28 Molecule and Activation
Markers in PB CD4+ T Cells
The influence of the therapy on CD28, CD40L, and CD69
expression is shown in Table 1 and Fig. 1. After MTX and
iTNF therapy, we noted a marked increase in the frequency of
PB CD28+ Th cells (p =0.006 and p =0.04, respectively); thus
a similarly expanded CD28+ cell population was seen in all
examined groups. OKT3 stimulation markedly diminished the
CD28+ T cell population to comparable values in all groups
(p ≤0.02).
Similarly to pre-treatment observations, the proportions of
activated PB CD4+ T cells with positive expression for
Table 1 Mean proportions (and standard deviation) of CD4+ Tcells co-expressing activatory CD28, CD40L, CD69, and inhibitory CTLA-4 molecules
in RA patients before and after therapy with MTX and/or iTNF
Groups %CD4+CD28+ T cells %CD4+CD40L+ T cells %CD4+CD69+ T cells %CD4+mCTLA-4+ T cells %CD4+cCTLA-4+ T cells 




87.1  9.7          72.9  10.8 
89.4  9.4          77.2  8.9 
 21.4  9.7          15.5 5.7 
 26.3  8.4          19.3 7.9 
 13.2  8.7         38.4  14.0 
 15.2  7.8         43.1  15.2 
 15.5  11.7          18.3  6.6 
 9.6  5.5              22.6  13.1 
 19.0  15.2         14.3 7.5 




88.8  8.1          63.1  14.6 
90.5  6.5          75.3  11.0 
16.9  14.8         16.0 8.5 
 18.9  8.3          16.0 10.2 
 8.7  6.8            28.2  21.5 
 11.1  6.1          33.1  19.1 
 11.8  8.5            18.6  10.2 
 11.2  9.2            18.5  7.4 
 9.2  10.2         15.4  15.8 
 9.6  8.7            10.1  10.0 
Controls 91.5  4.0              80.2 8.6  2.5  0.9             12.1  4.3  2.1  1.1            44.2 10.6  8.2  3.2              16.1  5.1  13.0  6.4          24.7 6.7 
P
Before therapy 
MTX vs iTNF 
MTX vs Controls 
iTNF vs Controls 
After therapy 
MTX vs iTNF 
MTX vs Controls 
iTNF vs Controls 
   NS                    NS 
   0.05                  NS 
   0.06                  0.001 
  NS                    NS 
  NS                    NS 
  NS                    NS 
  0.03                     NS 
  0.00002               NS 
  0.00002               NS 
  0.01                     NS 
  0.00003               NS 
  0.0002                 NS 
  0.04                   NS 
  0.0001               NS 
  0.001                 0.02 
  0.07                   NS 
  0.00001             NS 
  0.0005                 NS 
  NS                       NS 
  0.02                     NS 
  NS                       NS 
  NS                       NS 
  NS                       NS 
  NS                       NS 
  0.008                   NS 
  NS                       0.02 
  NS                       0.008 
  NS                       NS 
  NS                       0.002 
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CD40L and CD69 were significantly enhanced in both groups
of RA patients compared to PB healthy cells (p ≤0.0005).
Remarkably, the occurrence of these activated cells in PB
from the iTNF group remained lower than in MTX patients
(p ≤0.07). Likewise, the frequency of circulating CD4+ T
cells co-expressing CD69 in both groups of treated RA
patients did not reach the physiological values found in
healthy T cells cultured under optimally stimulating condi-
tions (p ≤0.00002). Compared to pre-stimulation values,
only in controls was an increase in CD40L+ cell frequency
after culture with OKT3 noted (p =0.001). In contrast, a
diminished proportion of cells from RA patients expressed
CD40L (p ≤0.05); nevertheless, the differences between all
groups were non-significant. Regarding CD69 antigen ex-
pression, the post-treatment response of T cells to OKT3
did not differ as compared with those observed in untreated
patients; thus the cells expressed a significantly higher
frequency of CD69 antigen after stimulation than corre-
sponding cells in PB (p ≤0.001), and reached similar levels
in all studied groups.
Fig. 1 Expression of CD4+ T cells co-expressing CD28, CD40L, and CD69 molecules in RA patients before and after 6 months of therapy (mean
proportion ± SD)
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The impact of the treatment on CTLA-4 expression within
the CD4+ T cell population is shown in Table 1 and Fig. 2.
After the therapy, a decrease with subsequent normalization of
the frequency of mCTLA-4+ T cells in the MTX group was
demonstrated (p =0.031). Therefore, there were no significant
differences in PB mCTLA-4 and cCTLA-4 expression in
CD4+ T cells between studied groups of treated patients and
controls. OKT3 stimulation led to a marked increment in the
frequency of mCTLA-4+ Th cells to similar values in all
individuals (p ≤0.01). As for cCTLA-4, after 48 h of culture
with OKT3, the cells from RA patients responded to stimula-
tion in the same way, their cells expressing the cCTLA-4
molecule in an unchanged proportion of CD4+ T cells; in
contrast, the frequency of healthy cCTLA-4+ Th cells signif-
icantly increased under ex vivo stimulating conditions
(p =0.003) to obviously higher values compared to those seen
in RA (p ≤0.002).
Proliferative Activity of PB CD4+ T Cells
The effect of the therapy on proliferation of CD4+ T lympho-
cytes is shown in Table 2. Treatment with MTX resulted in
either spontaneous or stimulated proliferation improvement of
CD4+ T cells (p =0.05 and p =0.03, respectively), thus leading
to normalization of both. In contrast, iTNF administration
influenced neither spontaneous nor stimulated proliferative ca-
pacity of CD4+ T cells; therefore they remained with a func-
tional defect compared to healthy T cells (p =0.05). Neverthe-
less, there were no significant differences in either the
unstimulated or the stimulated proliferation rate of CD4+ T
cells from treated patients, although it seemed that the cells
obtained from the iTNF group underwent weaker cell division.
Discussion
In the current study we report dysregulated expression of the
activator and suppressor molecules within the population of
PB CD4+ T cells in RA patients before and after 6 months of
different therapeutic interventions. Furthermore, the observed
alterations seem to be pronounced during disease progression.
In particular, we observed that in the peripheral circulation in
the course of RA, there is an expansion of CD4+ Tcells lacking
the co-stimulatory CD28 molecule. It is noteworthy that the
magnitude of the CD4+CD28- T cell population was similar in
both groups of studied patients with different duration of the
active disease. In many autoimmune diseases, such as Crohn’s
disease [16], juvenile idiopathic arthritis [17], ankylosing spon-
dylitis [18], and multiple sclerosis [19], an unusually high
proportion of CD28- T cells in the periphery was also found.
Fig. 2 Expression of CD4+ Tcells co-expressing membrane/surface CTLA-4 (mCTLA-4) and cytoplasmic CTLA-4 (cCTLA-4) in RA patients before
and after 6 months of therapy (mean proportion ± SD)
240 A. Kosmaczewska et al.
Also, normal aging is related to increased loss of both the CD28
molecule and immunocompetence. Our finding parallels sever-
al studies demonstrating a decreased CD4+CD28+ T cell pop-
ulation in RA, which is disproportionally diminished with
patients’ age [20, 21]. In fact, the RATcell pool is characterized
by premature aging correlated with the loss of CD28 [22].
CD28 expression on T cells is normally modulated following
T cell activation with transient down-regulation early after stim-
ulation [23]. Thus the loss of CD28 expression on PB CD4+ T
cells in RA patients could reflect chronic immune stimulation by
arthrogenic antigens or continuous activation in a cytokine-rich
microenvironment with the prime position of TNF-alpha [23,
24]. This cytokine plays a role as the dominant repressor of
CD28 gene transcription and has been found up-regulated in
RA sera [25]. The impact of the in vivo activation on CD28
expression decline is consistent with studies showing that repeat-
ed stimulation of T lymphocytes in long-term culture may lead to
progressive loss of the CD28 molecule [26]. Consistently with
the above suggestion, our data also show significant down-
regulation of the CD28 T cell pool when T cells are cultured
with additional stimulation with OKT3, more pronounced in
patients with progressive RA. Also, the extensive TNF-alpha
half-life in the culture and post-culture estimation cannot be
neglected due to its known interaction with membrane proteins
[27], resulting in the maintenance of TNF-alpha biologic action
for a longer period. Thus, membrane-bound TNF-alpha might
reveal its prolonged inhibitory effect on CD28 expression in the
culture. The OKT3-mediated CD28 defect found in the most
advanced RA is in agreement with the previous demonstration
that the frequency of CD28- T cells is correlated with severity of
RA [28]. Nonetheless, this alteration is reversible irrespective of
the disease duration and type of therapeutic intervention. The
reversal of CD28 deficit seems to be associated more with the
clinical outcome of RA therapy [16], which is in line with our
observation of post-treatment clinical improvement in almost all
patients even if RA remission usually did not occur.
The suggestion on chronic in vivo stimulation of CD4+ T
cells is consistent with other findings of the significantly in-
creased expression of both the activation markers CD40L and
CD69 in all RA patients as well as inducible antigen CTLA-4 in
those in the early phase of RA. Furthermore, CD40L and CD69
antigens were found to be strongly interrelated in all patients at
every time point tested, as was also previously demonstrated
[12]. Based on the observation that CD40L expression is closely
correlated with CD39, a lymphoid activation marker with
prolonged expression after activation [29], we can speculate that
CD40L+ cells represent a subset of CD4+ T cells that have
undergone prolonged and increased activation. The variability
of CD40L and CD69 antigen expression found between both
groups of patients favors the interpretation that at distinct phases
of the disease, patients’ lymphocytes undergo activation with
different intensity. Therefore, CD4+ T cells from patients with
early RA exhibited the highest extent of systemic activation
compared to those obtained from progressive disease. This could
be caused by the fact that patients qualified for iTNF adminis-
tration were under intensified immunosuppressive treatment,
including MTX and other DMARD medications. The second
explanation is related to possible CD4+ T cell exhaustion in
advanced RA due to prolonged in vivo activation. The observa-
tion that OKT3-stimulated CD69 expression in this group of
Table 2 Proliferative capacity of CD4+ T cells in RA patients before and after 6 months of therapy (mean proportion ± SD)
Proliferative 
activity
MTX group iTNF group Controls 
before after before after 
Spontaneous 0.138 0.052 0.162 0.055 0.110 0.069 0.150  0.053 0.186 0.035 
OKT3-
stimulated 
0.151 0.060 0.177  0.066 0.126 0.083 0.169 0.072 0.205 0.042 









Activatory and inhibitory potential of PB CD4+ T cells in RA 241
patients did not reach the level of activation observed in corre-
sponding cells from controls seemed to confirm this suggestion.
Given also that DNA demethylation of the X-linked gene
CD40L in CD4+ T cells from women with RA corresponded
with increased CD40L expression, together with our observation
of female preponderance in the group of RA patients examined, a
role of genetic factors in CD40L overexpression in RA cannot be
excluded [30].
In addition, we did not observe post-treatment normalization
in the expression of activationmarkers in PB. The percentages of
CD40L+ and CD69+ cells within CD4+ T cells remained at a
markedly higher level in PB of RA patients even after 6 months
of therapy with MTX and/or iTNF. Yet, an increase of the
CD40L+ T helper cell pool in the circulation of MTX patients
was seen, which may result from CD28 post-treatment increase,
as the correlated dynamics of their expressions have been previ-
ously demonstrated in RA [31]. We suggest that reversal of
systemic activation in RA could be related to clinical outcome
after therapeutic interventions. In fact, almost all patients enrolled
in the current study did not achieve clinical remission, which
corresponded with the maintenance of increased clinical and
laboratory markers of inflammation.
The variability between both groups of patients also
concerned the fraction of CD4+ T cells co-expressing inhibi-
tory CTLA-4 molecule inducible upon activation. Its in-
creased expression on the surface of T cells from the MTX
group strengthens the suggestion of the highest extent of
in vivo activation in untreated patients in early disease. On
the other hand, CTLA-4 plays a key role in T cell inhibition,
thus indicating a potency for sufficient termination of the
ongoing T cell activation in early RA. OKT3 stimulation did
not change surface CTLA-4 expression in the same group
despite the intact cytoplasmic compartment of CTLA-4 mol-
ecules, suggesting that the activation in vivo had occurred to a
maximal extent. In contrast, patients with progressive RA
exhibited impaired suppressor potential in PB CD4+ T cells,
considering affected cytoplasmic CTLA-4 expression, proba-
bly due to T cell exhaustion related to disease progression. In
addition, this also could be a result of immunosuppressive
agent administration in the past. Nevertheless, ex vivo re-
stimulation revealed an intrinsic defect in CTLA-4-mediated
suppression in the CD4+ T cell pool in all RA patients either
before or after the therapeutic intervention, suggesting that the
inhibitory potential declined progressively during prolonged
activation in RA, which is in line with the previous observa-
tions in other autoimmune diseases [32].
We suggest that the dysregulated expression of the examined
molecules with capacity for interfering with cell signaling
might have functional implications. To verify this hypothesis,
we extended our recent functional study assessing the capacity
of RA CD4+ T cells for secretion of cytokines (unpublished
data) and performed the proliferation assay. At entry to the
study, all RA patients exhibited profoundly defective
proliferative activity of T cells under either unstimulated or
stimulated conditions. This observation is in line with previous
studies [33–35]. The impaired overall proliferative capacity of
Tcells in RA has been attributed to premature senescence of PB
T cells in established disease. Rheumatoid arthritis-related ag-
ing of CD4+ T cells is characterized e.g. by shorter telomerase
length resulting from repeated in vivo stimulation and the loss
of CD28 expression especially in the most severe RA [34, 36].
Accordingly, in the present study, the most evident proliferative
defect was observed in progressive RA. Our recent finding that
within the CD4+ T cell compartment from the same RA pa-
tients, only those with advanced and long-lasting disease
exhibited a profoundly and irreversibly defected Th1 cell pop-
ulation, other subsets having similarly expanded, clearly shows
quantitative disturbances within the existing pool of lympho-
cytes during RA evolution (unpublished data). Furthermore, we
demonstrated that patients with early and short-term active
disease treated with MTX had a higher potency for restoration
of T cell proliferative capacity. In contrast, those with advanced
RA possessed a profound proliferative defect even after therapy
with iTNF. Consistently, the previous reports showed that iTNF
addition into the culture delayed loss of CD28 and led to only
transient proliferation improvement, resulting nonetheless in an
overall decrease in the ex vivo rate of CD4+ Tcell proliferation
[37]. Remarkably, after multiple rounds of cell division, the
cells did reach the non-proliferative end stage of replicative
senescence, thus being arrested in the G0/G1 phase of the cell
cycle [35, 37, 38]. In addition, RA-related aging Tcells showed
both a significant reduction in the production of IL-2 and an
increase in IL-6 secretion, thus supporting the shift in the
cytokine balance towards pro-inflammatory conditions. Simi-
larly disturbed imbalance in serum IL-2/IL-6 concentration,
confirming the functional impairment of PB CD4+ T lympho-
cytes more pronounced in progressive RA, was observed by
our group recently (unpublished data). The post-treatment
maintenance of affected proliferative capacity in RA related to
disease evolution has also been demonstrated [22], which is
consistent with our present findings.
In summary, our data demonstrate that patients with vary-
ing severity of RA exhibit several abnormalities of the
activatory and inhibitory potential of PB CD4+ T cells corre-
sponding with the impaired proliferative capacity. The ob-
served alterations of the immune system develop progressive-
ly and might facilitate progression of the disease by affecting
the effector functions of CD4+ T lymphocytes.
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